June 29, 2022 -- A $10 million collaboration between the Mark Foundation for Cancer Research, the Bloomberg-Kimmel Institute (BKI) for Cancer Immunotherapy, and the Johns Hopkins University seeks to advance the development of next-generation genomics and imaging platforms for cancer immunotherapy.
The Mark Foundation, whose research priorities include studying how cancer evades the immune system and spreads, is donating $6 million and BKI is providing $4 million to help scientific teams to continue using innovative technologies to determine why certain patients do not respond to immunotherapies.
"We are reimagining how technology can solve the complex cancer problem, a key mission of the Mark Foundation Center for Advanced Genomics and Imaging," said Dr. Drew Pardoll, PhD, BKI director and professor of oncology.
Among the technologies that are of interest are single-cell genomics, which look at the inner workings of individual tumor cells and all the cells in and around it, and imaging technologies together with artificial intelligence, to simplify the complex immune-tumor interactions within the tumor microenvironment.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: